Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers.

INTRODUCTION: As an endeavor to control SARS-CoV-2 infection, the Moderna vaccine booster was given to healthcare workers to prevent reinfection and reduce the risk of complications from COVID-19. A heterologous booster vaccine is also thought to provide better protection against the current SARS-CoV-2 variants of concern. However, research that evaluates the effectiveness of the Moderna vaccine booster and the resulting SARS-CoV-2 antibody concentration is needed. OBJECTIVE: To evaluate the concentration of SARS-CoV-2 antibodies after the Moderna vaccine booster and the severity of SARS-CoV-2 infection before and after the Moderna vaccine booster. RESULTS: A total of 93 healthcare providers who received Moderna vaccine booster were included in the study. Examination of antibody concentration 3 months after the booster showed an average concentration of 10081.65 U/mL. There was an increase in antibody concentration before the booster and 3 months after, from a median of 1.7 U/mL to 9540 U/mL. Every subject showed a statistically significant increment of antibody concentration 3 months after the booster (p < 0.01). Thirty-seven (39.8%) subjects received two doses of the Sinovac vaccine and were confirmed to have COVID-19 with the Delta variant. After the booster, 26 (28%) subjects were infected with the Omicron Variant. Among the subjects who received two doses of the Sinovac vaccine and were confirmed with COVID-19, 36 (30.1%) had mild symptoms, and 1 (1.1%) was asymptomatic. CONCLUSIONS: Heterologous Moderna vaccine booster effectively increases antibody response against SARS-CoV-2 variants and shows mild symptoms of COVID-19 infection.

Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records.

Prior research generally finds that the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) COVID-19 vaccines provide similar protection against mortality, sometimes with a Moderna advantage due to slower waning. However, most comparisons do not address selection effects for those who are vaccinated and with which vaccine. We report evidence on large selection effects, and use a novel method to control for these effects. Instead of directly studying COVID-19 mortality, we study the COVID-19 excess mortality percentage (CEMP), defined as the COVID-19 deaths divided by non-COVID-19 natural deaths for the same population, converted to a percentage. The CEMP measure uses non-COVID-19 natural deaths to proxy for population health and control for selection effects. We report the relative mortality risk (RMR) for each vaccine relative to the unvaccinated population and to the other vaccine, using linked mortality and vaccination records for all adults in Milwaukee County, Wisconsin, from 1 April 2021 through 30 June 2022. For two-dose vaccinees aged 60+, RMRs for Pfizer vaccinees were consistently over twice those for Moderna, and averaged 248% of Moderna (95% CI = 175%,353%). In the Omicron period, Pfizer RMR was 57% versus 23% for Moderna. Both vaccines demonstrated waning of two-dose effectiveness over time, especially for ages 60+. For booster recipients, the Pfizer-Moderna gap is much smaller and statistically insignificant. A possible explanation for the Moderna advantage for older persons is the higher Moderna dose of 100 µg, versus 30 µg for Pfizer. Younger persons (aged 18-59) were well-protected against death by two doses of either vaccine, and highly protected by three doses (no deaths among over 100,000 vaccinees). These results support the importance of a booster dose for ages 60+, especially for Pfizer recipients. They suggest, but do not prove, that a larger vaccine dose may be appropriate for older persons than for younger persons.

Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine.

Coronavirus disease 2019 (COVID-19) is a disease characterized by predominantly respiratory symptoms, which can progress to respiratory failure. Due to the novelty of the vaccines, it is difficult to assess if there are any associated long-term side effects. Here, we present a case of an elderly female who received the Moderna COVID-19 vaccine and developed a high-grade sarcoma at the site of the injection. A 73-year-old female with a past medical history of hypertension, hyperlipidemia, and renal angiomyolipoma status post resection in 2019 presented with worsening right upper arm swelling for the past two weeks. She noticed the swelling two to four days after receiving her second dose of the Moderna vaccine within 1 cm from the prior injection site. Physical examination was remarkable for a 6 cm, circular, mobile, soft mass present in the right upper arm. MRI with and without contrast revealed a 5.2 cm soft tissue mass overlying the triceps region with irregular features concerning for malignancy. Fine needle aspiration revealed pathologic characteristics indicative of high-grade sarcoma. The patient ultimately had resection of the mass four months after the initial visit and was diagnosed as having grade 3, stage IIIA undifferentiated, pleomorphic high-grade sarcoma. Herein, we present a case demonstrating the development of high-grade sarcoma at the injection site in an elderly female patient within days of receiving the second dose of the Moderna COVID-19 vaccine. Currently, it is unclear whether there is a true association between the vaccines and malignancy or inflammatory response exacerbating underlying malignancy. This case highlights the necessity to investigate and be aware of such rare, adverse complications that may be associated with the novel COVID-19 vaccinations to guide physicians in their differential diagnosis.

Comparing health consumer search behavior and scientific research productivity related to COVID-19 vaccines in the USA: an infodemiology study

PurposeWhile vaccines are an effective preventative measure to defend against the spread and harmful symptoms of COVID-19, information about COVID vaccines can be difficult to find and conflicting in its coverage of vaccines' benefits and risks. This study aims to examine the extent to which Americans are searching for information about the three major vaccine producers (Pfizer-BioNTech, Moderna and Johnson & Johnson's Janssen) in relation to the amount of reliable scholarly information that has been produced about each one.Design/methodology/approachData were retrieved from Google Trends for the US Web users alongside scientific research output of the US scientists toward three Centers for Disease Control and Prevention (CDC)-authorized COVID-19 vaccines in Web of Science, Scopus and PubMed. The authors searched for descriptive statistical analyses to detect coronavirus-seeking behavior versus coronavirus releases in the USA from May 1, 2020, to April 30, 2021.FindingsOf the three COVID-19 vaccines, Pfizer has attracted more attention from the US population. However, the greatest number of articles about COVID-19 vaccines published by the US scholars belonged to Moderna (M = 8.17), with Pfizer (M = 7.75) having slightly less, and Janssen (M = 0.83) well behind. A positive association was found between COVID-19 vaccine information-seeking behavior (ISB) on Google and the amount of research produced about that vaccine (P <0.001).Research limitations/implicationsAs the researchers use the single search engine, Google, to retrieve data from the USA, thus, selection bias will be existing as Google only gathers the data of people who chose to get the information by using this search engine.Practical implicationsIf the policymakers in the US Department of Health and Human Services or the US CDC desire to improve the country's health ISB and the scientific publication behavior (SPB) of the US researchers regarding COVID-19 vaccines studies, they should reference the results of such a study.Originality/valueFrom an infodemiological viewpoint, these findings may support the health policymakers, as well as researchers who work on COVID-19 vaccines in the USA.

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review.

INTRODUCTION: Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273). However, Phase 3 studies are insufficient to detect rare adverse events (AEs). A literature search of the two major electronic databases, Embase and PubMed, was performed to enable the identification and characterization of all relevant articles from December 2020 to November 2022. AREAS COVERED: This narrative review summarizes the key safety outcomes associated with the mRNA-1273 vaccine to inform healthcare decisions and increase public awareness of mRNA-1273 vaccine safety. The primary adverse events (AEs) reported within a diverse population, receiving the mRNA-1273 vaccine, were; localized injection site pain, fatigue, headache, myalgia, and chills. In addition, the mRNA-1273 vaccine was also associated with; less than a 1-day change in the menstrual cycle, a 10-fold higher risk of myocarditis and pericarditis within young males aged 18-29 years and increased levels of anti-polyethylene glycol (PEG) antibodies. EXPERT OPINION: The transient nature of commonly observed AEs and the rare occurrence of severe events within mRNA-1273 recipients show no significant safety concerns which should prevent vaccination. However, large-scale epidemiological studies with longer follow-up periods are required to surveillance rare safety outcomes.

Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.

INTRODUCTION: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted accelerated vaccine development of novel messenger RNA (mRNA)-based vaccines by Moderna and Pfizer, which received FDA Emergency Use Authorization in December 2020. The purpose of this study was to examine trends in primary series administration and multi-dose completion rates with Moderna's mRNA-1273 vaccine administered at a United States retail pharmacy. METHODS: Walgreens pharmacy data were joined to publicly available data sets to examine trends in mRNA-1273 primary series and multi-dose completion across patient race/ethnicity, age, gender, distance to first vaccination, and community characteristics. Eligible patients received their first dose of mRNA-1273 administered by Walgreens between December 18, 2020 and February 28, 2022. Variables significantly associated with on-time second dose (all patients) and third dose (immunocompromised patients) in univariate analyses were included in linear regression models. A subset of patients in selected states were studied to identify differences in early and late vaccine adoption. RESULTS: Patients (N = 4,870,915) who received ≥ 1 dose of mRNA-1273 were 57.0% White, 52.6% female, and averaged 49.4 years old. Approximately 85% of patients received a second dose during the study period. Factors associated with on-time second dose administration included older age, race/ethnicity, traveling ≤ 10 miles for the first dose, higher community-level health insurance, and residing in areas with low social vulnerability. Only 51.0% of immunocompromised patients received the third dose as recommended. Factors associated with third dose administration included older age, race/ethnicity, and small-town residence. Early adopters accounted for 60.6% of patients. Factors associated with early adoption included older age, race/ethnicity, and metropolitan residence. CONCLUSION: Over 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion. Novel approaches to facilitate series completion during a pandemic should be further studied.

Supraventricular tachycardia and deep vein thrombosis following Moderna vaccination: A case series.

There have been reports of deep vein thrombosis and supraventricular tachycardia following the Moderna vaccination. The timing of SVT and DVT just after vaccination in our case series could suggest possible temporal relationships to the vaccination. But further studies are needed to establish such evidence.

Numerical Simulation for a Hybrid Variable-Order Multi-Vaccination COVID-19 Mathematical Model

In this paper, a hybrid variable-order mathematical model for multi-vaccination COVID-19 is analyzed. The hybrid variable-order derivative is defined as a linear combination of the variable-order integral of Riemann–Liouville and the variable-order Caputo derivative. A symmetry parameter σ is presented in order to be consistent with the physical model problem. The existence, uniqueness, boundedness and positivity of the proposed model are given. Moreover, the stability of the proposed model is discussed. The theta finite difference method with the discretization of the hybrid variable-order operator is developed for solving numerically the model problem. This method can be explicit or fully implicit with a large stability region depending on values of the factor Θ. The convergence and stability analysis of the proposed method are proved. Moreover, the fourth order generalized Runge–Kutta method is also used to study the proposed model. Comparative studies and numerical examples are presented. We found that the proposed model is also more general than the model in the previous study;the results obtained by the proposed method are more stable than previous research in this area.

Covid-19 Vaccines and mRNA Technology: Not as New as Many Believe

When the mRNA COVID-19 vaccines were announced in December 2020 the world was excited that a vaccine was available to combat the coronavirus pandemic. One of the most frequent comments was a desire to wait because the vaccine technology was "so new.” This article will concentrate on the mRNA vaccines not familiar to the public and is intended to explain the developmental timeline before and after the genome of COVID-19 was announced. We discuss Operation Warp Speed and SARS-CoV-2 and specifically the development of Messenger RNA (mRNA) vaccines and concurrent other types of vaccines. Other topics of discussion include COVID-19 variants;effectiveness of mRNA vaccines;and late news about the Pfizer-BioNTech COVID-19 vaccine. The article conclusion discusses implications for nurses as they continue to follow future developments, become competent in communicating viral epidemiology, and educate patients and families about vaccine options © 2022,Online Journal of Issues in Nursing. All Rights Reserved.

Vaccination in Mexico as a Political Strategy

Worldwide vaccination has reduced hospitalization and lethality of COVID-19. However, access to vaccines has not been homogeneous across regions and individual countries have shaped their own strategy for the distribution and application of vaccines. In Mexico, vaccination started in November 2020. This chapter reviews Mexico's vaccination strategy and its coverage in comparison with other countries and the impact of vaccination on mortality rates. We also analyze if vaccination may have been used as a political strategy given its application patterns before two major events, i.e., midterm elections and a public consultation. Finally, we evaluate socioeconomic variables across states to predict the vaccination coverage state-wise. We found that as of January 2022, almost 60% of Mexicans has been vaccinated. Thus, mortality associated to COVID-19 has reduced compared with the three previous contagion waves. Finally, the socioeconomic variable that better explain differences across states in terms of vaccination coverage was the percentage of rural population, that is, vaccination was lower where rural population was highest. This result goes against the Mexican federal strategy of protecting the most vulnerable regions first, where rural population was the largest. © TheEditor(s) (ifapplicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021, 2022.

A Bibliometric Analysis of Moderna mRNA-1273 Vaccine for COVID-19

We performed the 1st bibliometric analysis of the Moderna mRNA-1273 vaccine (for COVID-19). On May 28, 2021, the data was retrieved from the Scopus database. In total, two hundred and three (n=203) documents are published about Moderna, majorly comprising of reviews (n=84) and articles (n=66). In all documents (reviews and articles only), 1110 authors have significantly contributed. The documents per author were 0.135, while authors per document were 7.4. The collaborative Index (CI) was 8.34. By Lotka's Law, we provided information about the frequency of authors. For example, 1021 authors were involved in one (n=1) publication. The total number of publications, h-index, m-index, g-index, and total citations for all authors are provided. The highest documents are published by the National Institutes of Health NIH (n-8) & Moderna Therapeutics (n=8 and the National Institute of Allergy and Infectious Diseases NIAID (n=7). Fifty-five (n=55) countries have significantly contributed to all publications. The highest documents are published by the United States (n=74), India (n=30), and the United Kingdom (n=16). By Biblioshiny, the co-authorship network is also presented. All documents are published in 118 different sources, majorly in Vaccines (n=6), Frontiers in Immunology (n=5), and New England Journal Of Medicine (n=4). We also provided the H-index, g-index, and m-index of all sources. The top ten (n-10) most cited documents are briefly discussed, while we provided a general overview of the publications by co-words analysis. On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine. © 2022 by the authors.

Fatal Post COVID mRNA-Vaccine Associated Cerebral Ischemia.

Background: Venous thromboses have been linked to several COVID-19 vaccines, but there is limited information on the Moderna vaccine's effect on the risk of arterial thrombosis. Here we describe a case of post-Moderna COVID-19 vaccination arterial infarct with vaccine-associated diffuse cortical edema that was complicated by refractory intracranial hypertension. Case Summary: 24 hrs after receiving her first dose of the Moderna COVID-19 vaccine, a 30-year-old female developed severe headache. Three weeks later she was admitted with subacute headache and confusion. Imaging initially showed scattered cortical thrombosis with an elevated opening pressure on lumbar puncture. An external ventricular drain was placed, but she continued to have elevated intracranial pressure. Ultimately, she required a hemicraniectomy, but intractable cerebral edema resulted in her death. Pathology was consistent with thrombosis and associated inflammatory response. Conclusion: Though correlational, her medical team surmised that the mRNA vaccine may have contributed to this presentation. The side effects of COVID-19 infection and vaccination are still incompletely understood. Though complications are rare, clinicians should be aware of presentations like this one.

Case Report: Psychiatric Symptoms Associated With the Moderna mRNA COVID-19 Vaccine Administration and Their Resolution.

This case report describes the sudden presentation and successful cessation of psychiatric symptoms following the first administration of the Moderna mRNA vaccine against the SARS-CoV-2 virus during early 2021. The process of discovery of symptoms is described, along with an empirical procedure which identified St. John's wort as the mediating agent. Implications for self-medication of mild depression are discussed. Hypericin, a constituent agent in St. John's wort, interacts with the SARS-CoV-2 spike protein. Sensitization to hypericin following vaccine administration is consistent with the observed symptoms.

Monitoring Mentions of COVID-19 Vaccine Side Effects on Japanese and Indonesian Twitter: Infodemiological Study.

Background: The year 2021 was marked by vaccinations against COVID-19, which spurred wider discussion among the general population, with some in favor and some against vaccination. Twitter, a popular social media platform, was instrumental in providing information about the COVID-19 vaccine and has been effective in observing public reactions. We focused on tweets from Japan and Indonesia, 2 countries with a large Twitter-using population, where concerns about side effects were consistently stated as a strong reason for vaccine hesitancy. Objective: This study aimed to investigate how Twitter was used to report vaccine-related side effects and to compare the mentions of these side effects from 2 messenger RNA (mRNA) vaccine types developed by Pfizer and Moderna, in Japan and Indonesia. Methods: We obtained tweet data from Twitter using Japanese and Indonesian keywords related to COVID-19 vaccines and their side effects from January 1, 2021, to December 31, 2021. We then removed users with a high frequency of tweets and merged the tweets from multiple users as a single sentence to focus on user-level analysis, resulting in a total of 214,165 users (Japan) and 12,289 users (Indonesia). Then, we filtered the data to select tweets mentioning Pfizer or Moderna only and removed tweets mentioning both. We compared the side effect counts to the public reports released by Pfizer and Moderna. Afterward, logistic regression models were used to compare the side effects for the Pfizer and Moderna vaccines for each country. Results: We observed some differences in the ratio of side effects between the public reports and tweets. Specifically, fever was mentioned much more frequently in tweets than would be expected based on the public reports. We also observed differences in side effects reported between Pfizer and Moderna vaccines from Japan and Indonesia, with more side effects reported for the Pfizer vaccine in Japanese tweets and more side effects with the Moderna vaccine reported in Indonesian tweets. Conclusions: We note the possible consequences of vaccine side effect surveillance on Twitter and information dissemination, in that fever appears to be over-represented. This could be due to fever possibly having a higher severity or measurability, and further implications are discussed.

Perceptions of the COVID-19 Vaccination among Health-care Professional in Dr. M. Djamil General Hospital Padang

AIM: It provides a comprehensive overview of coronavirus disease 19 (COVID-19) vaccination perception of health-care professionals in Dr. M. Djamil General Hospital, Padang, West Sumatera, Indonesia. METHOD(S): This study was conducted from August to September 2021. We assessed perceptions using a questionnaire survey of the health workers and disseminated using Google form. Data entry and analysis were conducted using IBM SPSS version 26. RESULT(S): A total of 645 health-care professionals participated in this study. The average age is 36.95 years with 70.35% female. Nurse and general practitioner had the highest positive perception on Sinovac (adjusted odds ratio [AOR] 7.130, 95% confidence interval (CI) 3.406-14.927, p < 0.001). Survivor of COVID-19 participants had lower positive perception on Sinovac compared to non-survivor (AOR 0.347 95% CI 0.208-0.579 p < 0.001). General practitioner had the highest positive perception on Moderna booster (AOR 5.918, 95% CI 1.804-19.414, p = 0.003). Participant who had positive perception on Sinovac also had higher positive perception on Moderna booster (AOR 13.548, 95% CI 6.689-27.442, p < 0.001). Participant with positive perception on Sinovac and Moderna booster more recommends vaccination to other compared to participant with negative perception (AOR 7.699, 95% CI 2.987-19.842, p < 0.001 and AOR 10.545, 95% CI 4.106-27.081, p < 0.001). CONCLUSION(S): Occupation and survivor of COVID-19 affecting the perceptions of vaccination. The health-care professional who had positive perception of vaccination would tend to recommend COVID-19 vaccination.Copyright © 2022 Raveinal Raveinal, Dwitya Elvira, Alexander Kam, Afdol Rahmadi, Abdul Alim Rahimi, Rivani Sintia Suratman, Annisa Ul Husni, M. Ridho Azhari.

Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?

SARS-CoV-2 causes Coronavirus Disease 2019 (COVID-19), an infectious condition that can present none or one or more of these symptoms: fever, cough, headache, sore throat, loss of taste and smell, aches, fatigue and musculoskeletal pain. For the prevention of COVID-19, there are vaccines available including those developed by Pfizer, Moderna, Sinovac, Janssen, and AstraZeneca. Recent evidence has shown that some COVID-19-vaccinated individuals can occasionally develop as a potential side effect Guillain-Barre syndrome (GBS), a severe neurological autoimmune condition in which the immune response against the peripheral nerve system (PNS) can result in significant morbidity. GBS had been linked previously to several viral or bacterial infections, and the finding of GBS after vaccination with certain COVID-19, while rare, should alert medical practitioners for an early diagnosis and targeted treatment. Here we review five cases of GBS that developed in different countries after COVID-19 vaccination.Copyright © 2021

Dermatological adverse effects of COVID-19 vaccines.

Studies for vaccine development have been completed in an unprecedented time to prevent further outbreak of the dangerous and potentially fatal coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Some of these vaccines have been approved by various authorities and made available worldwide. While vaccine applications continue globally, the number of dermatological side effects reported after vaccination is increasing daily. Many cutaneous reactions have been reported in the literature, such as injection site reactions, pernio lesions, pityriasis rosacea, herpes zoster, and exacerbations of chronic inflammatory dermatoses such as atopic dermatitis and psoriasis. Most COVID-19 vaccines require two doses and a booster dose, and considering the new variants of the coronavirus, vaccination is estimated to continue for a while. In this context, dermatologists are more likely to encounter vaccine-related dermatological side effects in their daily practice. Dermatologists play an essential role in many issues such as diagnosis and treatment of cutaneous reactions after COVID-19 vaccination, informing patients and providing necessary counseling. This perspective will also provide helpful information for the future in terms of vaccination strategies to be developed for repeated doses. In this study, most of the cutaneous reactions reported after COVID-19 vaccination in the current literature are reviewed.Copyright © Telif Hakki 2022 Deri ve Zuhrevi Hastaliklar Dernegi.

Dermatological adverse effects of COVID-19 vaccines.

Studies for vaccine development have been completed in an unprecedented time to prevent further outbreak of the dangerous and potentially fatal coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Some of these vaccines have been approved by various authorities and made available worldwide. While vaccine applications continue globally, the number of dermatological side effects reported after vaccination is increasing daily. Many cutaneous reactions have been reported in the literature, such as injection site reactions, pernio lesions, pityriasis rosacea, herpes zoster, and exacerbations of chronic inflammatory dermatoses such as atopic dermatitis and psoriasis. Most COVID-19 vaccines require two doses and a booster dose, and considering the new variants of the coronavirus, vaccination is estimated to continue for a while. In this context, dermatologists are more likely to encounter vaccine-related dermatological side effects in their daily practice. Dermatologists play an essential role in many issues such as diagnosis and treatment of cutaneous reactions after COVID-19 vaccination, informing patients and providing necessary counseling. This perspective will also provide helpful information for the future in terms of vaccination strategies to be developed for repeated doses. In this study, most of the cutaneous reactions reported after COVID-19 vaccination in the current literature are reviewed.Copyright © Telif Hakki 2022 Deri ve Zuhrevi Hastaliklar Dernegi.

Adverse events following immunization with COVID-19 vaccines

Objective: The purpose of this study was to identify Post-Vaccination Adverse Events (PVAE) with Moderna vaccine, locally systemically, and other reactions. Methods: A quantitative descriptive research method with a retrospective approach was used in this study. The study was carried out at RSUD Cicalengka Bandung with a population of employees who had received the Moderna vaccine after two complete doses of Sinovac from August to September 2021. Purposive sampling was used, with a total of 162 respondents calculated using the Yamane formula. Result: The results of this study showed that all respondents (100 %) had experienced PVAE after Moderna vaccination. The PVAEs were classified as systemic (95.1 %), local (92.6 %), and other (53.1 %). Fever (75.9 %) in systemic PVAEs, pain (92 %) in local PVAEs, and lymphadenopathy (25.9 %) in other PVAEs had the highest percentage of reactions. A significant proportion of respondents (27.5 %) reported being unable to work following the Moderna vaccination. Conclusions: PVAE can occur following Moderna vaccination and result in the inability to work, potentially causing service problems. Employees must be scheduled for planned vaccinations and monitored for PVAE to reduce the possibility of adverse effects. © 2023 Academia Nacional de Medicina. All rights reserved.